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Abstract  30 
Therapeutic vaccinations have a potential application in infections where no curative 31 
treatment is available. In contrast to HIV, efficacious vaccines for a cat retrovirus, 32 
feline leukemia virus (FeLV), are commercially available. However, the infection is 33 
still prevalent, and no effective treatment of the infection is known. By vaccinating 34 
persistently FeLV-infected cats and presenting FeLV antigens to the immune system 35 
of the host, e.g., in the form of recombinant and/or adjuvanted antigens, we intended 36 
to shift the balance toward an advantage of the host so that persistent infection could 37 
be overcome by the infected cat. Two commercially available FeLV vaccines 38 
efficacious in protecting naïve cats from FeLV infection were tested in six 39 
experimentally and persistently FeLV-infected cats: first, a canarypox-vectored 40 
vaccine, and second, an adjuvanted, recombinant envelope vaccine was repeatedly 41 
administered with the aim to stimulate the immune system. No beneficial effects on 42 
p27 antigen and plasma viral RNA loads, anti-FeLV antibodies or life expectancy of 43 
the cats were detected. The cats were unable to overcome or decrease viremia. Some 44 
cats developed antibodies to FeLV antigens although not protective. Thus, we cannot 45 
recommend vaccinating persistently FeLV-infected cats as a means of improving their 46 
FeLV status, quality of life or life expectancy. We suggest testing of all cats for FeLV 47 
infection prior to FeLV vaccination.  48 
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Abbreviations 52 
EDTA, Ethylenediaminetetraacetic acid; ELISA, enzyme-linked immunosorbent 53 
assay; FeLV, Feline Leukemia Virus; HBV,  hepatitis B virus; HCV, hepatitis C 54 
virus; TNA, total nucleic acid; 55 
56 
 - 5 - 
1. Introduction 57 
Treatment of many chronic infectious diseases remains a challenge. Present curative 58 
treatments are often either nonexistent (e.g., HIV/AIDS), inefficient (e.g., hepatitis B 59 
virus [HBV] infection) or remain toxic (e.g., IFN-α tolerance in hepatitis C virus 60 
[HCV] treatment)[1]. Thus, new classes of therapeutics are being developed, 61 
including therapeutic vaccines. Therapeutic vaccines have the potential to act in areas 62 
where no optimal treatment has been identified. Their underlying technology can be 63 
peptide or protein-based, vector-based (DNA, virus or bacteria-derived vectors), 64 
whole cell-based, or antigen-antibody-based. Their range of potential applications is 65 
enormous and includes areas such as oncology and infectious diseases, such as HBV 66 
and HCV, papillomaviruses or tuberculosis. Most of these therapeutic vaccines are 67 
currently in clinical trials (phase 1 and 2), but some have already reached the market. 68 
Naïve cats are able to mount a successful immune response after vaccination against 69 
FeLV and, in the majority of cats, also after natural infection. This outcome has been 70 
described as abortive or regressive infection; the cats show no viremia (abortive) or 71 
only transient viremia and low proviral and viral RNA loads (regressive). However, in 72 
about a third of the unvaccinated cats exposed to FeLV the immune system fails to 73 
develop a successful FeLV-specific response, and the cat develops a persistent 74 
infection with fatal outcome due to subsequent FeLV-associated diseases [2-4]. 75 
Persistent infection is characterized by persistence of antigenemia and high provirus 76 
and plasma viral RNA loads.  77 
By vaccinating clinically healthy, persistently infected cats and presenting the FeLV 78 
antigens to the immune system (e.g., in the form of recombinant and/or adjuvanted 79 
antigens), we intended to shift the balance, at least temporarily, toward an advantage 80 
of the host, so that persistent infection can be overcome by the infected cat. 81 
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To stimulate the immune system, two commercially available vaccines were chosen 82 
which were both shown to be highly efficacious in preventing FeLV infections [5-8]. 83 
They differ in their composition and mode of action: the first, Purevax® FeLV, is a 84 
recombinant, canarypox-vectored live vaccine and is assumed to stimulate the cellular 85 
immune system through activation of phagocytes, antigen-specific cytotoxic T-86 
lymphocytes and the release of cytokines in response to an antigen; the second, 87 
Leucogen®, an adjuvanted recombinant envelope protein vaccine, was associated 88 
with the induction of a strong humoral immune response. We hypothesize that 89 
through stimulation of the immune system by therapeutic vaccination, the boost of the 90 
immune system may lead to a reduction of the virus load either through antibody-91 
mediated action or through the cellular immune response. Thus, it was the aim of this 92 
study to repeatedly vaccinate persistently FeLV-infected cats and follow the presence 93 
and quantity of plasma viral RNA, p27 antigen and anti-FeLV antibody levels. 94 
2. Materials and methods 95 
2.1. Sample collection from experimentally infected domestic cats 96 
All six specified pathogen-free (SPF) cats included in this study were in experimental 97 
studies officially approved by the veterinary office of the Swiss Canton of Zurich 98 
(11/2011, 160/2010 and 251/2013). The cats were kept in groups under optimal 99 
ethological conditions in a barrier facility, as previously described [9]. They had been 100 
experimentally infected with FeLV-A/Glasgow-1 within the above mentioned studies 101 
[10, 11] between the ages of 10 to 21 weeks (median age = 18 weeks); 0.7 to 1.5 years 102 
after infection therapeutic vaccination was started (median duration of infection = 1.5 103 
years). Because there were six cats available with persistent infection at the time, all 104 
cats were assigned to the treatment group, while a historical control group was used 105 
for comparison of the p27 antigen levels as it had been reported in a previous study 106 
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[11]. The five cats in the control group were matched with the cats in the treatment 107 
group for duration of FeLV infection (median infection duration at the time point of 108 
the start of this study = 1.6 years); moreover, the age at the time point of experimental 109 
infection in the cats of the control group was matched to that of the treatment group 110 
(median age = 18 weeks)[12]. Identical methods were used for the analysis of samples 111 
from cats in the treatment and the control group. EDTA-anticoagulated whole blood 112 
samples were collected at three to four week intervals from all cats in the treatment 113 
group and at seven to nine week intervals in the historical control group. The general 114 
condition of the cats was monitored daily by the animal care takers and thorough 115 
clinical examinations were performed weekly by veterinarians. Complete hemograms 116 
were performed using a Sysmex XT-2000iV (Sysmex Corporation, Kobe, Japan) [13]. 117 
For the white blood cell differential, microscopic blood smear evaluation was 118 
performed, as described [14]. 119 
Three cats (CK1, CK3 and BZ3) had to be euthanized for humane reasons during the 120 
vaccination and follow-up period and underwent necropsy and histopathological 121 
examination. 122 
2.2. FeLV vaccination 123 
Two types of FeLV vaccines were tested in the current study. First, the cats in the 124 
treatment group were vaccinated subcutaneously five times with a non-adjuvanted 125 
canarypox-vectored live vaccine (ALVAC) containing FeLV-A env, gag and part of 126 
pol (Purevax® FeLV, Biokema S.A., Crissier, Switzerland) at three week intervals. 127 
The cats were then followed for another 13 weeks. Then, the cats were vaccinated 128 
with a second vaccine, an adjuvanted recombinant protein vaccine containing the 129 
envelope glycoprotein of FeLV-A expressed in Escherichia coli (Leucogen®, Virbac, 130 
Glattbrugg, Switzerland). The non-glycosylated recombinant protein includes the 131 
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entire exterior envelope protein (p45) plus the first 34 amino acids of the 132 
transmembrane protein p15E [6]. Again, all cats were vaccinated five times at three to 133 
four week intervals and subsequently followed for another 13 weeks. The vaccination 134 
intervals were chosen according to the manufacturers recommendations 135 
(www.emea.europa.eu). 136 
2.3. Serological assays 137 
The level of FeLV antigenemia was determined by p27 antigen sandwich ELISA as 138 
described [15]. Values above 4% of the positive control run with each assay were 139 
considered positive [7]. Anti-FeLV whole virus antibodies were measured by ELISA 140 
using 500 ng of gradient purified antigen per well, as described previously [16, 17].  141 
Antibodies to recombinant p15E and the non-glycosylated p45 env gene product were 142 
measured by ELISA as described [5, 18]. The antibody levels were expressed in 143 
relation to a positive and negative control that was run on each plate; for calculation 144 
of standardized optical density values see [18]. 145 
2.4. Nucleic acid extraction 146 
Total nucleic acid (TNA) was extracted from 200 µl EDTA plasma using the MagNA 147 
Pure LC Total Nucleic Acid Isolation Kit (Roche Diagnostics, Rotkreuz, 148 
Switzerland), and the TNA was analyzed for the presence of viral RNA by real-time 149 
TaqMan RT-PCR, as described previously [19]. Negative controls consisting of 150 
100 µl of phosphate buffered saline (PBS) were prepared with each batch to monitor 151 
cross-contamination. 152 
 153 
2.5. Statistics 154 
Statistical analyses were performed using GraphPad Prism for Windows, Version 4.03 155 
(GraphPad software, San Diego, CA). The time course of p27 levels, plasma viral 156 
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RNA loads, FeLV specific antibodies and hematological parameters within a group 157 
were analyzed using the non-parametric Friedman test for paired samples (pF) 158 
followed by the Dunn’s Multiple Comparison test (pD). The frequency of cats that had 159 
to be euthanized during the study in the different groups was compared using the 160 
Fisher’s exact test (pFisher). A p-value less than 0.05 was considered significant. 161 
3. Results and discussion 162 
The first round of therapeutic vaccination was initiated by repeatedly vaccinating the 163 
six persistently FeLV-infected cats with a recombinant, canarypox-vectored vaccine. 164 
Virus blood loads were followed using p27 antigen ELISA and real-time TaqMan RT-165 
PCR for plasma viral RNA. During the first vaccination and follow-up period, p27 166 
antigen levels did not show a decrease (Figure 1A). In contrast, 18 and 23 weeks after 167 
the first vaccination, FeLV antigen levels had significantly increased compared to 168 
week 0 (Figure 1A). No significant changes in antigen levels were detected in FeLV-169 
infected historical controls matched with the treated group for weeks after 170 
experimental infection (Figure 1B). Plasma viral RNA loads in the treated group 171 
remained stable during the entire observation period (Figure 1C). Prior to the 172 
experiment, all cats had undetectable levels of antibodies to FeLV whole virus and the 173 
recombinant p45 env gene product (Figure 2A and B). Vaccination did not lead to an 174 
increase of these FeLV specific antibodies; they remained at background levels (≤ 175 
1.5%) at all times in all cats (Figure 2A and B). This is in accordance with previous 176 
observations in naïve cats where vaccination with the canarypox-vectored vaccine did 177 
not lead to production of anti-FeLV specific antibodies; although the cats were 178 
subsequently efficaciously protected from FeLV challenge infection [7, 8]. 179 
Alternatively, if antibodies were produced in the persistently infected cats, they might 180 
have been bound in vivo by the circulating virus. Antibodies to p15E were low in all 181 
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cats (< 27%); lowest levels were found in cats CK1 and CK3 (Figure 2C). A slight 182 
overall decrease of antibodies to p15E was found during vaccination with the 183 
canarypox vectored vaccine (pF = 0.0379; Figure 2C). Hematological parameters, 184 
such as hematocrit, leucocyte count, and neutrophil and eosinophil granulocyte counts 185 
did not show any significant changes over time, although some cats had developed 186 
anemia (hematocrit <33%), leukopenia and/or neutropenia (Supplementary Figure 1). 187 
Moreover a significant decrease (pF = 0.0029) was found in lymphocyte counts in 188 
treated cats between week 3 and 25 after the first vaccination (pD < 0.05; 189 
Supplementary Figure 1B). Hematological results of the historical control cats were 190 
not available. One cat (CK1) displayed severe lymphopenia (340 cells/µl) and had to 191 
be euthanized for humane reasons during the first part of the experiment in week 10. 192 
The cat had shown increasing p27 levels (185%, Figure 1A) and no anti-FeLV 193 
specific antibodies prior to clinical deterioration (Figure 2). The pathological 194 
examination revealed that this cat had developed a T-cell lymphoma in the 195 
mediastinum. Lymphoma is a fatal disease frequently associated with FeLV infection 196 
[20, 21]. Thirteen weeks after the last vaccination with the canarypox-vectored 197 
vaccine, a second cat (CK3) had to be euthanized for humane reasons prior to the start 198 
of the second experiment. Again this cat had shown increasing p27 levels (121% at 199 
the time of euthanasia in week 25, data not shown) and undetectable anti-FeLV 200 
antibodies (Figure 2). The cat had developed chronic kidney disease leading to 201 
azotemia and anemia (3619 reticulocytes/µl; Supplementary Figure 1); upon necropsy 202 
severe bilateral membranous glomerulonephritis most likely associated with FeLV 203 
infection was diagnosed. Overall, the first vaccination series with the canarypox-204 
vectored vaccine did not show any beneficial effects on the presence of virus, anti-205 
FeLV antibodies, clinical parameters or health status of the cats.  206 
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The second round of repeated vaccinations using an adjuvanted recombinant protein 207 
vaccine was started with the remaining four cats. No significant changes in FeLV 208 
loads (p27 antigen and plasma viral RNA) were found during the second part of the 209 
study in the treated cats (Figure 3). Prior to the vaccinations, all cats had undetectable 210 
levels of antibodies to FeLV whole virus and the recombinant p45 env gene product 211 
(Figure 4A and B). During vaccinations with the recombinant envelope protein 212 
vaccine, a significant increase of antibodies to p45 was detected (week 0 to 28: pF = 213 
0.0137; week 0 to 19: pF = 0.0069; Figure 4B). To the best of our knowledge this is 214 
the first demonstration of significant antibody production to an adjuvanted FeLV 215 
envelope protein vaccine in long-term persistently FeLV-infected cats. One of the cats 216 
(BP2) developed levels of antibody approaching those observed in naïve cats (Figure 217 
4B) vaccinated with the recombinant env vaccine [5], the remaining cats developed 218 
lower antibody levels. This is similar to what had been found in an earlier study, 219 
where persistently FeLV-infected cats were vaccinated against rabies: those cats 220 
developed neutralizing antibodies to the rabies vaccines although to a lower level than 221 
FeLV uninfected cats [22]. Moreover, cats persistently infected with FeLV developed 222 
antibodies to synthetic peptides (TGAL, tetanus toxoid) but delayed and to much 223 
lower levels compared with FeLV uninfected cats [23, 24]. Low antibody levels 224 
against p15E were found (< 20% of the positive control) and no significant change 225 
could be observed during the study period in antibodies to p15E. In addition, the 226 
hematological parameters did not show any significant changes in the vaccinated cats 227 
during the second set of vaccinations and in the 13 weeks thereafter; some cats were 228 
anemic, leukopenic, neutropenic and/or lymphopenic (Supplementary Figure 2 and 229 
data not shown). The differences between the developments of lymphocyte counts 230 
during the two vaccination studies might be the result of the different modes of 231 
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actions of the two vaccines (primarily cellular versus humoral immune response). Of 232 
note, the statistical power in the second set of experiments was smaller than in the 233 
first one due to a smaller number of cats in the treated group. Historical control 234 
samples matched for weeks after experimental FeLV infection did not show any 235 
significant changes in p27 levels during the time frame observed (Figure 3B). One cat 236 
(BZ3) had to be euthanized six weeks after the last vaccination with the recombinant 237 
protein vaccine, and necropsy revealed T-cell lymphoma in the mediastinum, 238 
pericardium, tonsils and prescapular lymph nodes with secondary leukemia. While 239 
antibody levels against p15E were undetectable in the two cats that had to be 240 
euthanized earlier (CK1 and CK3), only very low levels were found in the third cat, 241 
BZ3, which had to be euthanized due to FeLV-associated disease (≤ 3.7% during the 242 
second round of repeated vaccinations; Figure 4C). This may indicate that low 243 
antibody levels against FeLV p15E might be an indicator of declining health in 244 
persistently FeLV-infected cats. In parallel, p27 levels showed a marked increase in 245 
the two previously and this third euthanized cat. In agreement with this in a recent 246 
study it was found that persistently FeLV-infected cats with fatal FeLV-associated 247 
disease had significantly higher blood p27 levels compared to healthy persistently 248 
FeLV-infected cats (unpublished observation). Thus, monitoring of these two 249 
parameters - blood p27 levels and anti-FeLV p15E antibodies - may be helpful 250 
prognostic parameters in persistently FeLV-infected cats. 251 
At the end of the experiment, 2.6 years after FeLV exposure, three of the initial six 252 
persistently FeLV-infected vaccinated cats had survived, while in the historical 253 
control group five out of five cats had survived during the same timeframe after 254 
infection (pFisher = 0.2). Although there is no significant difference between the two 255 
groups in survival of the cats, as a precaution, we recommend not vaccinating 256 
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persistently infected cats, and in accordance with the manufacturers, we suggest 257 
testing of all cats for FeLV infection prior to FeLV vaccination. Of note, at the time 258 
point of submission of this article, the three remaining persistently infected cats were 259 
still alive (3.1 years after FeLV infection). 260 
Our results indicate that vaccination of cats persistently infected with FeLV – at least 261 
at the time point chosen, 1.5 years after FeLV infection - does not improve the health 262 
status of the cats or decrease the virus load. No improvement in the vital parameters 263 
was observed in any of the cats. Thus, the authors refrained from initiating larger 264 
studies with more cats or analyzing additional parameters investigating e.g., the 265 
cellular immune response in these cats.  266 
In contrast to our data, several therapeutic vaccinations have been applied 267 
successfully in human medicine, e.g., against cancer: Provenge® vaccine, which aims 268 
at treating prostate cancer was the first FDA approved therapeutic cancer vaccine 269 
[25]. Furthermore, therapeutic vaccination also against a virus, the human papilloma 270 
virus, demonstrated significant overall response rates and DNA-based viral clearance 271 
in phase II trials [1]. Similar to our study, and despite over 15 years of intensive 272 
research, no effective therapeutic vaccine has been developed against the human 273 
retrovirus HIV and AIDS. Although numerous phase I and II trials are ongoing or 274 
have already been completed, overall these vaccines have not yet yielded convincing 275 
data [1]. However, it needs to be noted that also no efficacious prophylactic vaccines 276 
are available against HIV, while very successful vaccines have been commercially 277 
available against FeLV for several decades [5, 7, 26]. 278 
 279 
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4. Conclusion 280 
Repeated vaccination with a canarypox-vectored vaccine or an adjuvanted 281 
recombinant protein vaccine did not shown any beneficial effect on p27 levels, viral 282 
RNA loads, anti-FeLV antibodies or survival of the cats. Therefore, we cannot 283 
recommend vaccinating persistently FeLV-infected cats as a means of improving their 284 
FeLV status, quality of life or life expectancy. Moreover, it seems advisable to test 285 
cats for the presence of viremia/antigenemia prior to FeLV vaccination. 286 
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 Figures 390 
Figure 1  - p27 antigen and plasma viral RNA loads of persistently FeLV 391 
infected cats after repeated FeLV vaccination with a recombinant, canarypox-392 
vectored vaccine. Persistently FeLV infected cats were vaccinated five times (grey 393 
box; arrows). A) FeLV p27 antigen levels in the peripheral blood of vaccinated cats, 394 
B) FeLV p27 antigen levels in the peripheral blood of historical controls matched for 395 
weeks after experimental infection, C) plasma viral RNA loads of vaccinated cats. 396 
FeLV p27 antigen levels and viral RNA loads were tested for significant differences 397 
by the non-parametric Friedmann test (pF) including only paired samples and the 398 
Dunn’s Multiple Comparison test: * = p <0.05; ** = p < 0.01. 399 
Figure 2  - Antibody levels of persistently FeLV infected cats after repeated 400 
FeLV vaccination with a recombinant, canarypox-vectored vaccine. A) 401 
Antibodies to FeLV whole virus, B) to p45 and C) to p15E as determined by ELISA. 402 
Time points of vaccination are indicated (grey box; arrows). Significant differences 403 
were determined with the non-parametric Friedmann test (pF), including only paired 404 
samples and the Dunn’s Multiple Comparison test: no significant differences could be 405 
detected. The cats CK1 and CK3 had to be euthanized due to humane reasons 406 
during and after the first part of the experiment in week 10; and week 25, 407 
respectively. 408 
 409 
Figure 3  - p27 antigen and plasma viral RNA loads of persistently FeLV 410 
infected cats after repeated FeLV vaccination with a recombinant protein 411 
vaccine. Persistently FeLV infected cats were vaccinated five times (grey box; 412 
 - 18 - 
arrows). A) FeLV p27 levels in the peripheral blood of vaccinated cats, B) FeLV p27 413 
antigen levels in the peripheral blood of historical controls matched for weeks after 414 
experimental infection, C) plasma viral RNA loads in the vaccinated cats. FeLV p27 415 
antigen levels and viral RNA loads were tested for significant differences by the non-416 
parametric Friedmann test (pF) including only paired samples and the Dunn’s 417 
Multiple Comparison test: no significant differences could be detected. 418 
Figure 4  - Antibody levels of persistently FeLV infected cats after repeated 419 
FeLV vaccination with a recombinant protein vaccine. A) Antibodies to FeLV 420 
whole virus, B) to p45 and C) to p15E as determined by ELISA. Time points of 421 
vaccination are indicated (grey box; arrows). Significant differences were determined 422 
with the non-parametric Friedmann test (pF), including only paired samples and the 423 
Dunn’s Multiple Comparison test: * = p <0.05. The cat BZ3 had to be euthanized due 424 
to humane reasons in week 21. 425 
 426 
Supplementary data 427 
Supplementary Figure 1 – Time course of hematological parameters of 428 
persistently FeLV infected cats after repeated FeLV vaccination with a 429 
canarypox-vectored vaccine. 430 
A) Hematocrit. B) Lymphocyte counts. Time points of vaccination are indicated by 431 
arrows, the reference ranges (5th to 95th percentiles) by shaded areas. 432 
 433 
Supplementary Figure 2 – Time course of hematological parameters of 434 
persistently FeLV infected cats after repeated FeLV vaccination with a 435 
recombinant protein vaccine. 436 
A) Hematocrit. B) Lymphocyte counts. Time points of vaccination are indicated by 437 
arrows, the reference ranges (5th to 95th percentiles) by shaded areas. 438 
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